← Leaderboards
Ronald D. Alvarez
University Of Alabama At Birmingham
$2,992,466
Attributed
$4,955,133
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $697.8K · FY2006–15$1M$750K$500K$250K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
Funding mix
By agency
NIH$4,955,133 · 5
By mechanism
P50$1,509,282 · 1
R01$1,252,799 · 1
U10$1,195,599 · 1
R21$551,000 · 1
K24$446,453 · 1
Top collaborators
- Cornelia L Trimble5 shared
- T.-C. Wu5 shared
- Jennifer De Los Santos3 shared
- Paolo Erba3 shared
- Carla I Falkson3 shared
- Andres Forero3 shared
Most similar at University Of Alabama At Birmingham
Same institution · by research overlap
- David T Curiel$31,690,411
- Charles A. Leath$2,454,862
- Amitkumar N Mehta$1,687,160
- Casey T Weaver$23,846,284
- Erica Michelle Stringer-Reasor$677,773
Others in their field
Top investigators on “Clinical Trials”
- Lawrence Corey · Fred Hutchinson Cancer Center$824,102,536
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$622,583,125
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,008,718
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$504,273,077
Research focus
Clinical TrialsMalignant NeoplasmsCancer PatientDiagnosisLeadResearch PersonnelGene TherapyTranslatingUniversitiesAlabamaWomanNext GenerationMalignant Neoplasm Of Cervix UteriProgramsToxic EffectClinical ResearchSafetyImmunologicsAffectResponseStagingPre-ClinicalCell DeathClinical Trial Phase I
Grant awards (18)
NCTN Deep South Research Consortium$497,800
U10 · FY2015 · CA · contact PI
NCTN Deep South Research Consortium$199,999
U10 · FY2015 · CA · contact PI
NCTN Deep South Research Consortium$497,800
U10 · FY2014 · CA · contact PI
A phase I trial to assess the safety and immunogenicity of repeated, cluster part$288,750
P50 · FY2013 · CA · contact PI
A phase I trial to assess the safety and immunogenicity of repeated, cluster part$309,265
P50 · FY2012 · CA · contact PI
A phase I trial to assess the safety and immunogenicity of repeated, cluster part$305,192
P50 · FY2011 · CA · contact PI
A phase I trial to assess the safety and immunogenicity of repeated, cluster part$301,914
P50 · FY2010 · CA · contact PI
A phase I trial to assess the safety and immunogenicity of repeated, cluster part$304,161
P50 · FY2009 · CA · contact PI
Infectivity Enhanced Virotherapy For Ovarian Cancer$275,500
R21 · FY2008 · CA · contact PI
Infectivity Enhanced Virotherapy For Ovarian Cancer$275,500
R21 · FY2007 · CA · contact PI
Enhanced Adenoviral Vectors for Ovarian Cancer$205,761
R01 · FY2007 · CA · contact PI
Enhanced Adenoviral Vectors for Ovarian Cancer$170,784
R01 · FY2006 · CA · contact PI
OVARIAN CANCER GENE THERAPY MIDCAREER CLINICAL SCIENTIST$112,863
K24 · FY2003 · CA
Enhanced Adenoviral Vectors for Ovarian Cancer$412,673
R01 · FY2002 · CA
OVARIAN CANCER GENE THERAPY MIDCAREER CLINICAL SCIENTIST$112,013
K24 · FY2002 · CA
Enhanced Adenoviral Vectors for Ovarian Cancer$463,581
R01 · FY2001 · CA
OVARIAN CANCER GENE THERAPY MIDCAREER CLINICAL SCIENTIST$111,189
K24 · FY2001 · CA
OVARIAN CANCER GENE THERAPY MIDCAREER CLINICAL SCIENTIST$110,388
K24 · FY2000 · CA